Since current clinical practice favors the use of the PSA test as an initial indicator of prostate cancer, complementing the PSA prediction model with a subset of flow cytometry predictions can increase the accuracy of the initial prostate cancer test and reduce the misclassified patient cases. The gene discussed is KLK3; the disease is prostate carcinoma.